Arbutus Biopharma: A Clinical-Stage Biotech with a Broad Patent Portfolio and Liposomal Drug Delivery Expertise.

Arbutus Biopharma is a clinical-stage biopharmaceutical company with expertise in liposomal drug delivery and RNA interference. It owns a diverse patent portfolio covering various drug delivery technologies and RNA interference methods. The company is involved in IP drama with high stakes, as it faces legal challenges from other companies trying to assert their own IP rights in these areas. Arbutus is focused on developing new treatments for diseases such as hepatitis B and COVID-19.

Arbutus Biopharma, a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, is engaged in a high-stakes legal battle with Moderna. The dispute revolves around the use of liposomal drug delivery technology, a critical component in Moderna's mRNA-based COVID-19 vaccines. Arbutus, known for its expertise in liposomal drug delivery and RNA interference, owns a broad and diverse patent portfolio covering various aspects of lipid nanoparticle (LNP) technology.

The litigation began in February 2022, when Arbutus and its subsidiary, Genevant, filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna. Arbutus alleges that Moderna used its patented technology without permission, claiming that the technology was crucial for the success of Moderna's COVID-19 vaccine. In response, Moderna sought to shift the blame to the U.S. government, arguing that the government, not Moderna, should be held liable for any infringement Arbutus: IP Drama With High Stakes^[1].

The court has denied Moderna's motions to dismiss the case, and the parties have exchanged cross-motions for summary judgment. The case is expected to proceed to trial, with Arbutus's chances of success bolstered by recent developments. Markman Advisors Zachary Silbersher, who has closely followed the case, notes that the dispute is nearing trial and that Arbutus has successfully navigated the legal process to this point Arbutus: IP Drama With High Stakes^[1].

Arbutus's focus on this litigation is evident in recent corporate changes. In February 2025, the company appointed Lindsay Androski as its new CEO and initiated a restructuring, terminating almost all in-house research work and laying off 57% of its workforce. The company's current market capitalization is nearly $850 million, but the value of its HBV program is difficult to measure Arbutus: IP Drama With High Stakes^[1].

The outcome of this legal battle is uncertain, but a successful resolution could significantly impact Arbutus's valuation. Despite the high stakes, investors should approach Arbutus with caution due to the uncertainties surrounding the case and the company's current market capitalization Arbutus: IP Drama With High Stakes^[1].